Mucosolvan in the treatment of patients with primary Sjögren's syndrome. Results from a double-blind cross-over investigation.
Thirty-six patients with primary Sjögren's syndrome were randomized to Mucosolvan (60 mg X 2 daily) or placebo, in a double-blind cross-over study. Each period of treatment was 3 weeks with 1 week wash-out in between. None of the objective ophthalmological tests (Schirmer-1-test, break-up time, van Bijsterveld score, cornea sensitivity, appearance of nuclear chromatin in conjunctival epithelial cells, tear lysozyme) improved during the investigation period.
D000328:Adult; D000368:Aged; D000551:Ambroxol / Q000627:therapeutic use*; D001964:Bromhexine / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012859:Sjogren's Syndrome / Q000188:drug therapy*
D000551:Ambroxol; D001964:Bromhexine